{"transactions":[{"id":1773288,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-26T22:00:28.000Z","date":"2023-09-25","kind":"sale","planned":false,"acquired":false,"shares":705,"price":1.06,"value":747.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2022 and February 28, 2023."}],"balance_after":451826,"source":{"system":"sec-edgar","filing":"0001453687-23-000067","document":"wk-form4_1695765617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000067/wk-form4_1695765617.xml","form_type":"4"}},{"id":2060292,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:15:28.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":20,"price":1.1114,"value":22.228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":446121,"source":{"system":"sec-edgar","filing":"0001453687-23-000032","document":"wf-form4_167304330841657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000032/wf-form4_167304330841657.xml","form_type":"4"}},{"id":2060291,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:15:28.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":3445,"price":1.1293,"value":3890.4385,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":446141,"source":{"system":"sec-edgar","filing":"0001453687-23-000032","document":"wf-form4_167304330841657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000032/wf-form4_167304330841657.xml","form_type":"4"}},{"id":2060290,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:15:28.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":15,"price":1.142,"value":17.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":449586,"source":{"system":"sec-edgar","filing":"0001453687-23-000032","document":"wf-form4_167304330841657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000032/wf-form4_167304330841657.xml","form_type":"4"}},{"id":2060289,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:15:28.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":8164,"price":1.1337,"value":9255.5268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":449601,"source":{"system":"sec-edgar","filing":"0001453687-23-000032","document":"wf-form4_167304330841657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000032/wf-form4_167304330841657.xml","form_type":"4"}},{"id":2067119,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-04T21:59:05.000Z","date":"2023-01-02","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":900000,"derivative":{"exercise_price":1.13,"expiration_date":"2033-01-01","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001453687-23-000015","document":"wf-form4_167286949656390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000015/wf-form4_167286949656390.xml","form_type":"4"}},{"id":2067118,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-04T21:59:05.000Z","date":"2023-01-02","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between March 1, 2022 and August 31, 2022."}],"balance_after":457765,"source":{"system":"sec-edgar","filing":"0001453687-23-000015","document":"wf-form4_167286949656390.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000015/wf-form4_167286949656390.xml","form_type":"4"}},{"id":2437214,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-12T21:15:20.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":65430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 103,165 unvested restricted stock units."}],"balance_after":149190,"source":{"system":"sec-edgar","filing":"0001284500-22-000003","document":"wf-form4_164202210716166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000128450022000003/wf-form4_164202210716166.xml","form_type":"4"}},{"id":2439950,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-07T21:18:49.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":3226,"price":3.0859,"value":9955.1134,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.99 to $3.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":251355,"source":{"system":"sec-edgar","filing":"0001453687-22-000034","document":"wf-form4_164159030863488.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000034/wf-form4_164159030863488.xml","form_type":"4"}},{"id":2443749,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-05T21:36:30.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":415900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":415900,"derivative":{"exercise_price":3.31,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":415900},"source":{"system":"sec-edgar","filing":"0001453687-22-000025","document":"wf-form4_164141856949283.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000025/wf-form4_164141856949283.xml","form_type":"4"}},{"id":2443748,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:36:30.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":90200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026."}],"balance_after":254581,"source":{"system":"sec-edgar","filing":"0001453687-22-000025","document":"wf-form4_164141856949283.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000025/wf-form4_164141856949283.xml","form_type":"4"}},{"id":2473351,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-14T22:17:03.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":4083,"price":2.9869,"value":12195.5127,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.94 to $3.0201. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164381,"source":{"system":"sec-edgar","filing":"0001453687-21-000186","document":"wf-form4_163952020317161.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000186/wf-form4_163952020317161.xml","form_type":"4"}},{"id":2477176,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-10T22:07:52.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the \"Performance RSUs\"), which were earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. The compensation committee of the board of directors of the Issuer has determined that the second of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on December 8, 2021,"}],"balance_after":168464,"source":{"system":"sec-edgar","filing":"0001453687-21-000176","document":"wf-form4_163917405252050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000176/wf-form4_163917405252050.xml","form_type":"4"}},{"id":2541515,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T22:08:00.000Z","date":"2021-10-13","kind":"sale","acquired":false,"shares":3636,"price":4.39,"value":15962.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.35 to $4.475. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":154714,"source":{"system":"sec-edgar","filing":"0001453687-21-000144","document":"wf-form4_163433566388493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000144/wf-form4_163433566388493.xml","form_type":"4"}},{"id":2548755,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:26:47.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the \"Performance RSUs\"), which may be earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. Any Performance RSUs will generally vest in two equal installments upon the dates of achievement of each of the two performance conditions, subject to continued employment, so long as each performance condition is met before December 31, 2021. The compensation committee of the board of directors of the Issuer has determined that the first of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on October 1, 2021."}],"balance_after":158350,"source":{"system":"sec-edgar","filing":"0001453687-21-000135","document":"wf-form4_163346558417377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000135/wf-form4_163346558417377.xml","form_type":"4"}},{"id":2557654,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-09-28T20:32:28.000Z","date":"2021-09-24","kind":"grant","acquired":true,"shares":54400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% on September 24, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":54400,"derivative":{"exercise_price":4.32,"expiration_date":"2031-09-23","underlying":"Common Stock","underlying_shares":54400},"source":{"system":"sec-edgar","filing":"0001453687-21-000121","document":"wf-form4_163286112666853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000121/wf-form4_163286112666853.xml","form_type":"4"}},{"id":2557653,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-28T20:32:28.000Z","date":"2021-09-24","kind":"grant","acquired":true,"shares":9100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on September 24, 2022. The remainder of the underlying shares will vest in three equalannual installments thereafter so that the underlying shares will be fully vested on September 24, 2025."}],"balance_after":144600,"source":{"system":"sec-edgar","filing":"0001453687-21-000121","document":"wf-form4_163286112666853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000121/wf-form4_163286112666853.xml","form_type":"4"}},{"id":2693176,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-27T22:00:56.000Z","date":"2021-05-26","kind":"purchase","acquired":true,"shares":20000,"price":3.9925,"value":79850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.959 to $4.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135500,"source":{"system":"sec-edgar","filing":"0001453687-21-000078","document":"wf-form4_162215281637006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000078/wf-form4_162215281637006.xml","form_type":"4"}},{"id":2695028,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-26T20:33:32.000Z","date":"2021-05-25","kind":"purchase","acquired":true,"shares":5000,"price":3.48,"value":17400.0,"ownership":{"direct":true},"balance_after":115500,"source":{"system":"sec-edgar","filing":"0001453687-21-000074","document":"wf-form4_162206119370229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000074/wf-form4_162206119370229.xml","form_type":"4"}},{"id":2695027,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-26T20:33:32.000Z","date":"2021-05-24","kind":"purchase","acquired":true,"shares":12500,"price":3.3198,"value":41497.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.315 to $3.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":110500,"source":{"system":"sec-edgar","filing":"0001453687-21-000074","document":"wf-form4_162206119370229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000074/wf-form4_162206119370229.xml","form_type":"4"}},{"id":2777511,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-19T21:34:25.000Z","date":"2021-03-18","kind":"purchase","acquired":true,"shares":10000,"price":4.5,"value":45000.0,"ownership":{"direct":true},"balance_after":98000,"source":{"system":"sec-edgar","filing":"0001453687-21-000035","document":"wf-form4_161618965117089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000035/wf-form4_161618965117089.xml","form_type":"4"}},{"id":2777510,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-19T21:34:25.000Z","date":"2021-03-17","kind":"purchase","acquired":true,"shares":10000,"price":4.5295,"value":45295.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.525 to $4.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":88000,"source":{"system":"sec-edgar","filing":"0001453687-21-000035","document":"wf-form4_161618965117089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000035/wf-form4_161618965117089.xml","form_type":"4"}},{"id":2910145,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-12T23:21:37.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":37735,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 56,027 unvested restricted stock units."}],"balance_after":83760,"source":{"system":"sec-edgar","filing":"0001284500-21-000003","document":"wf-form4_161049368350061.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000128450021000003/wf-form4_161049368350061.xml","form_type":"4"}},{"id":2915396,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-06T21:50:33.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":230000,"derivative":{"exercise_price":2.99,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001453687-21-000018","document":"wf-form4_160996981436015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000018/wf-form4_160996981436015.xml","form_type":"4"}},{"id":2915395,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-06T21:50:33.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025."}],"balance_after":78000,"source":{"system":"sec-edgar","filing":"0001453687-21-000018","document":"wf-form4_160996981436015.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000018/wf-form4_160996981436015.xml","form_type":"4"}},{"id":2942423,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-16T21:31:17.000Z","date":"2020-12-14","kind":"purchase","acquired":true,"shares":40000,"price":3.2356,"value":129424.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.165 to $3.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001453687-20-000133","document":"wf-form4_160815426408163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368720000133/wf-form4_160815426408163.xml","form_type":"4"}},{"id":3069517,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-04T20:36:27.000Z","date":"2020-08-01","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% on August 1, 2021.  The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":650000,"derivative":{"exercise_price":2.38,"expiration_date":"2030-07-31","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001453687-20-000090","document":"wf-form4_159657328133721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368720000090/wf-form4_159657328133721.xml","form_type":"4"}},{"id":3312106,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-01-14T21:19:35.000Z","date":"2020-01-13","kind":"grant","acquired":true,"shares":18292,"price":3.28,"value":59997.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 18,292 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 13, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 18,292 unvested restricted stock units."}],"balance_after":46025,"source":{"system":"sec-edgar","filing":"0001284500-20-000002","document":"wf-form4_157903675526265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000128450020000002/wf-form4_157903675526265.xml","form_type":"4"}},{"id":3695047,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-01-16T21:13:19.000Z","date":"2019-01-14","kind":"grant","acquired":true,"shares":12121,"price":4.95,"value":59998.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 12,121 unvested restricted stock units."}],"balance_after":27733,"source":{"system":"sec-edgar","filing":"0001284500-19-000009","document":"wf-form4_154767318336251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000128450019000009/wf-form4_154767318336251.xml","form_type":"4"}},{"id":3698602,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-10T17:28:08.000Z","date":"2019-01-08","kind":"grant","acquired":true,"shares":8747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 8,747 shares underlying restricted stock granted under the 2018 Equity Incentive Compensation Plan which were awarded on January 8, 2018 and which vested on January 8, 2019."}],"balance_after":15612,"source":{"system":"sec-edgar","filing":"0001284500-19-000006","document":"wf-form4_154714127155595.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000128450019000006/wf-form4_154714127155595.xml","form_type":"4"}},{"id":3892759,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock option (right to buy)","published_at":"2018-06-15T20:02:54.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":50000,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179022-18-000054","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000054/edgar.xml","form_type":"4"}},{"id":3892758,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-15T20:02:54.000Z","date":"2018-06-13","kind":"sale","acquired":false,"shares":100000,"price":7.51,"value":751000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":107333,"source":{"system":"sec-edgar","filing":"0001179022-18-000054","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000054/edgar.xml","form_type":"4"}},{"id":3892757,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-15T20:02:54.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":100000,"price":0.87,"value":87000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":207333,"source":{"system":"sec-edgar","filing":"0001179022-18-000054","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000054/edgar.xml","form_type":"4"}},{"id":3897148,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock option (right to buy)","published_at":"2018-06-12T20:51:00.000Z","date":"2018-06-08","kind":"exercise","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":150000,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001179022-18-000050","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000050/edgar.xml","form_type":"4"}},{"id":3897147,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-12T20:51:00.000Z","date":"2018-06-08","kind":"sale","acquired":false,"shares":70000,"price":5.8571,"value":409997.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":107333,"source":{"system":"sec-edgar","filing":"0001179022-18-000050","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000050/edgar.xml","form_type":"4"}},{"id":3897146,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-12T20:51:00.000Z","date":"2018-06-08","kind":"exercise","acquired":true,"shares":70000,"price":0.87,"value":60900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":177333,"source":{"system":"sec-edgar","filing":"0001179022-18-000050","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000050/edgar.xml","form_type":"4"}},{"id":3918920,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock option (right to buy)","published_at":"2018-05-24T20:50:13.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018."}],"balance_after":125000,"derivative":{"exercise_price":4.16,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001179022-18-000039","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000039/edgar.xml","form_type":"4"}},{"id":4098080,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock option (right to buy)","published_at":"2018-01-17T21:34:33.000Z","date":"2018-01-15","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% immediately, 25% on June 30, 2018, and 50% on December 31, 2018."}],"balance_after":125000,"derivative":{"exercise_price":5.87,"expiration_date":"2028-01-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001179022-18-000010","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000010/edgar.xml","form_type":"4"}},{"id":4102463,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-01-10T21:05:00.000Z","date":"2018-01-08","kind":"grant","acquired":true,"shares":8747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in full on the date that is one year from the date of grant."}],"balance_after":8747,"derivative":{"exercise_date":"2019-01-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":8747},"source":{"system":"sec-edgar","filing":"0001144204-18-001693","document":"tv483048_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000114420418001693/tv483048_4.xml","form_type":"4"}},{"id":4314546,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-18T21:00:49.000Z","date":"2017-05-16","kind":"grant","acquired":true,"shares":2565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of 2,565 Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 750 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017, 1,650 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018, 2,565 shares of unvested Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018 and 312 shares of unvested restricted stock granted under the Issuer's 2009 Equity Compensation Plan that will vest quarterly through June 2, 2018."}],"balance_after":6865,"source":{"system":"sec-edgar","filing":"0001144204-17-028454","document":"v467409_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000114420417028454/v467409_4.xml","form_type":"4"}},{"id":4476250,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to Purchase Common Stock","published_at":"2017-01-31T23:51:37.000Z","date":"2017-01-09","kind":"grant","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2750,"derivative":{"exercise_price":3.54,"exercise_date":"2018-01-09","expiration_date":"2027-01-09","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001144204-17-005184","document":"v458003_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/320017/000114420417005184/v458003_4.xml","form_type":"4"}},{"id":4476249,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-31T23:51:37.000Z","date":"2017-01-09","kind":"grant","acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans."}],"balance_after":4300,"source":{"system":"sec-edgar","filing":"0001144204-17-005184","document":"v458003_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000114420417005184/v458003_4.xml","form_type":"4"}},{"id":4531515,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":109436,"kind":"person","name":"TRABER PETER G","position":1,"cik":"0001284500","reported_name":"TRABER PETER G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock option (right to buy)","published_at":"2016-12-06T22:10:06.000Z","date":"2016-12-03","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% immediately, 25% on July 1, 2017, and 50% on December 31, 2017."}],"balance_after":220000,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001179022-16-000123","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902216000123/edgar.xml","form_type":"4"}}]}